These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15533760)

  • 1. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel.
    Wernyj RP; Morin PJ
    Drug Resist Updat; 2004; 7(4-5):227-32. PubMed ID: 15533760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
    Farrell NP
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocapsules of platinum anticancer drugs: development towards therapeutic use.
    Bryde S; de Kroon AI
    Future Med Chem; 2009 Nov; 1(8):1467-80. PubMed ID: 21426060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The resurgence of platinum-based cancer chemotherapy.
    Kelland L
    Nat Rev Cancer; 2007 Aug; 7(8):573-84. PubMed ID: 17625587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of platinum compounds and their possible combination.
    Pasetto LM; D'Andrea MR; Brandes AA; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):59-75. PubMed ID: 16806960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excision repair cross complementing-group 1: gene expression and platinum resistance.
    Altaha R; Liang X; Yu JJ; Reed E
    Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
    Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
    Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.
    Takano M; Fujii K; Kita T; Kikuchi Y; Uchida K
    Oncol Rep; 2004 Dec; 12(6):1177-82. PubMed ID: 15547734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.